Phase 1
N=3
Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT00638651 ↗Enrolled (actual)
3
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Efficacy of Tattoo Removal Using Topical Imiquimod 5% Cream — 4.3; 2.7 percentage of tattoo pigment removed
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- 1064 nm Nd:YAG laser (Device); Imiquimod, 5% cream (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Miami
- Primary completion
- Aug 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy of Tattoo Removal Using Topical Imiquimod 5% Cream |
4.3; 2.7 | — |
Summary
The purpose of this study is to evaluate the efficacy of tattoo removal using topical imiquimod, 5% cream in conjunction with the 1064nm Nd:YAG laser. This procedure for tattoo removal will be compared to a laser removal alone.
Eligibility Criteria
Inclusion Criteria
- 2 tattoos no larger than 25cm2, professionally made, with approximately the same age, containing blue/black ink.
Exclusion Criteria
- Hypersensitivity to imiquimod
- Current sun tan
- Use of vitamin E, non-steroid anti-inflammatory drugs, coumadin or aspirin for the past 10 days
- Amateur tattoos
- Pregnancy
- Breast-feeding status
- Immunosuppression
- Auto-immune diseases.
Data sourced from ClinicalTrials.gov (NCT00638651). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.